Activating point mutations of the gsp oncogene in human thyroid adenomas
β Scribed by Catriona O'Sullivan; Claire M. Barton; Susan L. Staddon; Christopher L. Brown; Nicholas R. Lemoine
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 575 KB
- Volume
- 4
- Category
- Article
- ISSN
- 0899-1987
No coin nor oath required. For personal study only.
β¦ Synopsis
The gene for the alpha polypeptide chain (alpha s) of the heterotrimeric G protein Gs can be activated to the putative oncogene gsp by specific point mutations at codons 201 and 227. Such mutations have been reported in 40% of human growth hormone-secreting pituitary adenomas and in a single autonomously functioning thyroid adenoma. We examined an archival series of 45 differentiated human thyroid tumors by polymerase chain reaction amplification and oligonucleotide hybridization to identify point mutations at each of the affected codons. Successful amplification was achieved in 38 cases, and activating mutations were identified in 5 of 13 (38%) autonomously functioning adenomas, but in none of 16 nonfunctioning adenomas, six papillary carcinomas, or three follicular carcinomas. Our results confirm that the gsp oncogene is involved in the pathogenesis of autonomously functioning tumors but do not support a role in other thyroid tumors.
π SIMILAR VOLUMES
## Abstract ## Background Characterization of the genetic background of pediatric thyroid carcinomas could aid in distinguishing between differently staged tumors with respect to treatment and prognosis. Two known genetic factors associated with thyroid carcinoma, the protoβoncogenes __gsp__ and _
## Abstract The mutagenicity of oxygen free radicals was studied in a forward mutation system. pEC plasmid containing the human cβHaβ__ras__β1 protoβoncogene was reacted with oxygen free radicals generated by Cu^2+^ and H~2~O~2~ and was then transfected into NIH/3T3 cells. Transformed foci were obs
Medullary thyroid carcinoma (MTC) may occur sporadically or as part of the autosomal dominant multiple endocrine neoplasia type 2 (MEN 2). Three hereditary forms of MEN 2 have been identified: MEN 2A, MEN 2B, and familial MTC (FMTC). Missense germ-line mutations in the RET protooncogene have been id